Literature DB >> 12782772

Mechanisms and management of diuretic resistance in congestive heart failure.

L K M De Bruyne1.   

Abstract

Diuretic drugs are used almost universally in patients with congestive heart failure, most frequently the potent loop diuretics. Despite their unproven effect on survival, their indisputable efficacy in relieving congestive symptoms makes them first line therapy for most patients. In the treatment of more advanced stages of heart failure diuretics may fail to control salt and water retention despite the use of appropriate doses. Diuretic resistance may be caused by decreased renal function and reduced and delayed peak concentrations of loop diuretics in the tubular fluid, but it can also be observed in the absence of these pharmacokinetic abnormalities. When the effect of a short acting diuretic has worn off, postdiuretic salt retention will occur during the rest of the day. Chronic treatment with a loop diuretic results in compensatory hypertrophy of epithelial cells downstream from the thick ascending limb and consequently its diuretic effect will be blunted. Strategies to overcome diuretic resistance include restriction of sodium intake, changes in dose, changes in timing, and combination diuretic therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782772      PMCID: PMC1742703          DOI: 10.1136/pmj.79.931.268

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  27 in total

Review 1.  Pathophysiology of chronic heart failure.

Authors:  M Packer
Journal:  Lancet       Date:  1992-07-11       Impact factor: 79.321

2.  Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.

Authors:  T P Dormans; J J van Meyel; P G Gerlag; Y Tan; F G Russel; P Smits
Journal:  J Am Coll Cardiol       Date:  1996-08       Impact factor: 24.094

3.  Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure.

Authors:  T P Dormans; P G Gerlag
Journal:  Eur Heart J       Date:  1996-12       Impact factor: 29.983

4.  Role of duration of diuretic effect in preventing sodium retention.

Authors:  J A Ferguson; K J Sundblad; P K Becker; J C Gorski; D W Rudy; D C Brater
Journal:  Clin Pharmacol Ther       Date:  1997-08       Impact factor: 6.875

5.  Functional assessment with electrocardiographic gated single-photon emission computed tomography improves the ability of technetium-99m sestamibi myocardial perfusion imaging to predict myocardial viability in patients undergoing revascularization.

Authors:  M G Levine; C C McGill; A W Ahlberg; M P White; S Giri; B Shareef; D Waters; G V Heller
Journal:  Am J Cardiol       Date:  1999-01-01       Impact factor: 2.778

6.  Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure.

Authors:  D Fliser; M Schröter; M Neubeck; E Ritz
Journal:  Kidney Int       Date:  1994-08       Impact factor: 10.612

7.  Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance.

Authors:  J J van Meyel; P Smits; T Dormans; P G Gerlag; F G Russel; F W Gribnau
Journal:  J Intern Med       Date:  1994-04       Impact factor: 8.989

8.  Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure.

Authors:  M Lahav; A Regev; P Ra'anani; E Theodor
Journal:  Chest       Date:  1992-09       Impact factor: 9.410

9.  Combination diuretic treatment in severe heart failure: a randomised controlled trial.

Authors:  K S Channer; K A McLean; P Lawson-Matthew; M Richardson
Journal:  Br Heart J       Date:  1994-02

10.  Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.

Authors:  D L Vargo; W G Kramer; P K Black; W B Smith; T Serpas; D C Brater
Journal:  Clin Pharmacol Ther       Date:  1995-06       Impact factor: 6.875

View more
  16 in total

1.  Ultrafiltration in patients with decompensated heart failure and diuretic resistance: an Asian centre's experience.

Authors:  Loon Yee Louis Teo; Choon Pin Lim; Chia Lee Neo; Lee Wah Teo; Swee Ling Elaine Ng; Laura Lihua Chan; Manish Kaushik; Kheng Leng David Sim
Journal:  Singapore Med J       Date:  2016-01-15       Impact factor: 1.858

Review 2.  Loop diuretics in chronic heart failure: how to manage congestion?

Authors:  Justas Simonavičius; Christian Knackstedt; Hans-Peter Brunner-La Rocca
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

3.  Diuretic therapy in acute decompensated heart failure--bolus or continuous?

Authors:  Pankaj Jariwala; Saratchandra Koduganti
Journal:  Indian Heart J       Date:  2014 May-Jun

Review 4.  Diuretic Treatment in Heart Failure.

Authors:  David H Ellison; G Michael Felker
Journal:  N Engl J Med       Date:  2017-11-16       Impact factor: 91.245

Review 5.  [Acute heart failure].

Authors:  U Janssens
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-06-13       Impact factor: 0.840

Review 6.  A perspective on diuretic resistance in chronic congestive heart failure.

Authors:  Niel Shah; Raef Madanieh; Mehmet Alkan; Muhammad U Dogar; Constantine E Kosmas; Timothy J Vittorio
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-07-20

Review 7.  Cardiorenal syndrome and the role of ultrafiltration in heart failure.

Authors:  Jason Prosek; Anil Agarwal; Samir V Parikh
Journal:  Curr Heart Fail Rep       Date:  2013-03

Review 8.  Management of Patients Admitted with Acute Decompensated Heart Failure.

Authors:  Selim R Krim; Patrick T Campbell; Sapna Desai; Stacy Mandras; Hamang Patel; Clement Eiswirth; Hector O Ventura
Journal:  Ochsner J       Date:  2015

9.  Heart failure and acute renal dysfunction in the cardiorenal syndrome.

Authors:  Rajinder S Chahal; Chukwuma A Chukwu; Paul R Kalra; Philip A Kalra
Journal:  Clin Med (Lond)       Date:  2020-03       Impact factor: 2.659

10.  Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.

Authors:  Matthew F Sammons; Sujay V Kharade; Kevin J Filipski; Markus Boehm; Aaron C Smith; Andre Shavnya; Dilinie P Fernando; Matthew S Dowling; Philip A Carpino; Neil A Castle; Shannon G Zellmer; Brett M Antonio; James R Gosset; Anthony Carlo; Jerod S Denton
Journal:  ACS Med Chem Lett       Date:  2018-01-19       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.